secwatch.observer — SEC 8-K summary
======================================

Issuer:     XWELL, Inc. (XWEL)
CIK:        0001410428
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001104659-24-089684
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XWELL Q2 2024 revenue up 14% to $9.3M; net loss narrows to $2.0M from $5.7M
---------------------------------------------------------------------------

- Revenue $9.3M (vs $8.2M Q2 2023); operating loss improved to $1.9M from $4.7M.
- Net loss attributable to XWELL was $2.0M, down from $5.7M in prior year quarter.
- Opened new XpresSpa at Philadelphia airport; plans NYC Penn Station later 2024.
- CDC issued new 3-year biosurveillance RFP; XpresTest bidding; contract value similar to prior.
- Closed $1.4M registered direct offering at $2.18/share; cash & marketable securities $18.4M, no debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410428/000110465924089684/0001104659-24-089684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410428/000110465924089684/tm2421605d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-089684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer